The Risks of Clinical Expression of Alzheimer’s Disease (AD) in People with Biomarkers of Alzheimer's Pathology
This IWG risk stratification classification recommends against diagnosis of AD based on BAP alone without its clinical expression. This AD classification lends itself to a tailored management approach and specific patient journeys for each of its groups.
Authors
- Nicolas Villain (ORCID: https://orcid.org/0000-0002-7429-4289)
- Howard Feldman (ORCID: https://orcid.org/0000-0002-9258-4538)
- Bruno Dubois
- Giovanni B. Frisoni
Institutions
- University of Geneva (CH)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- University of California San Diego (US)
- Sorbonne Université (FR)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- University Hospital of Geneva (CH)
- Institut de Myologie (FR)
- Institut du Cerveau (FR)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_107831
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00